Owlstone Medical

About Owlstone Medical

Owlstone Medical is a leader in breath biomarker research and development, focusing on non-invasive diagnostic tests for early disease detection and precision medicine in areas such as cancer, respiratory, gastrointestinal, microbiome, and liver diseases. Their mission is to save 100,000 lives and $1.5 billion in healthcare costs by developing a breathalyzer for disease.

Products & Services

Breath Biopsy®:A platform for non-invasive breath analysis to detect volatile organic compounds (VOCs) for early disease detection and research.

Breath Biopsy Collection Station:A device for collecting breath samples for analysis.

OMED Health Breath Analyzer for Research:A breath analysis tool designed for research purposes.

LIBRA® Liver Function Test:A breath-based test for assessing liver function in research settings.

The Breath Biopsy® Microbiome Panel:A panel for analyzing microbiome-related biomarkers through breath.

SiHuB Sensor Calibration System:A system for calibrating sensors used in breath analysis.

ultraFAIMS™:A technology for high-sensitivity detection of VOCs in breath analysis.

EVOC® Probes:Tools for targeted VOC biomarker detection in breath research.

In vitro VOC Sampling:Services for sampling VOCs from cell cultures for research.

Breath Biopsy Collection Station

Breath Biopsy OMNI

LIBRA

Breath Biopsy Microbiome Panel

SiHuB

UltraFAIMS

VOC Atlas

EVOC Probes

Specialties

Breath Biomarker Research Non-Invasive Diagnostics Volatile Organic Compound (VOC) Analysis Early Disease Detection Precision Medicine Cancer Detection Respiratory Diseases Liver Disease Microbiome Analysis FAIMS Technology Breath Biopsy VOC analysis Early disease detection Precision medicine FAIMS technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 49100000 MR: - FA: up to $49.1 million FAN: 49100000	D: 2025-10-06 FD: 2025-10-06	1 investors
2	RT: Series E T: - FT: Series E	A: 27000000 MR: - FA: $27 million FAN: 27000000	D: 2025-01-15 FD: 2025-01-15	4 investors
3	RT: Equity Investment and Grant Funding T: - FT: Equity Investment and Grant Funding	A: 6500000 MR: - FA: $6.5 million FAN: 6500000	D: 2024-04-25 FD: 2024-04-25	1 investors

Grant Latest

2025-10-06

$49.1M

1 investor (Pro only)

Series E 2025-01-15

$27.0M

Equity Investment and Grant Funding 2024-04-25

$6.5M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Billy Boyle

Co-Founder and CEO

B

Bret Bader

CEO Owlstone Inc

A

Andy Richards

Non-Executive Director

D

Doug Wright

Medical Director Aviva

M

Mark Capone

CEO at Precision Medicine Advisors

P

Patrick Zhang

Investor at Horizons Ventures

View 33 more team members with Pro

Unlock Full Team Directory

Recent News